Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy-A Single Center Prospective Cohort Study.
Transplant Cell Ther
; 28(5): 278.e1-278.e4, 2022 05.
Article
em En
| MEDLINE
| ID: mdl-35182795
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos Quiméricos
/
COVID-19
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
Transplant Cell Ther
Ano de publicação:
2022
Tipo de documento:
Article